Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews discusses effective immunotherapy with markers of immune activation in metastatic prostate cancer.
While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab.
รขโฌลOur results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,รขโฌย said lead authorรย Sumit Subudhi, M.D., Ph.D., assistant professor ofรย Genitourinary Medical Oncology. รขโฌลWe found specific markers among a subset of patients with the greatest benefit, such as T-cell density and interferon-รยณ signaling, that may help improve our ability to select patients for treatment with checkpoint blockade.รขโฌย